Analytic Evaluation of a Human ELISA Kit for Measurement of Inhibin B in Rat Samples
Version of Record online: 24 JAN 2013
© 2013 Wiley Periodicals, Inc.
Birth Defects Research Part B: Developmental and Reproductive Toxicology
Special Issue: Part B: Developmental and Reproductive Toxicology
Volume 98, Issue 1, pages 4–16, February 2013
How to Cite
Coulson, M., Bickerton, S., Betts, C. J., Jacobsen, M., Stewart, J., Chapin, R. E., Reagan, W. J., Alvey, J., Erdos, Z., Saldutti, L. P., Sonee, M., Bogdan, N., Singer, M., Vinken, P., Barlow, V., Czajkowski, K. and Kim, J. H. (2013), Analytic Evaluation of a Human ELISA Kit for Measurement of Inhibin B in Rat Samples. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 98: 4–16. doi: 10.1002/bdrb.21047
- Issue online: 5 FEB 2013
- Version of Record online: 24 JAN 2013
- Manuscript Received: 13 DEC 2012
- Manuscript Accepted: 13 DEC 2012
- inhibin B;
A cross-laboratory analytic evaluation of a commercially available human inhibin B ELISA for measuring inhibin B in rat serum and plasma has been undertaken.
Dilution linearity, spiked recovery, intra- and inter-assay precision, functional sensitivity, matrix effects, and frozen stability were assessed across five laboratories. Reference ranges were generated for male Sprague Dawley and Han Wistar rats.
Acceptable performance was defined as an overall assay coefficient of variation ≤ 20% with an intraday LLOQ ≤ 20 pg/ml. Intra- and inter-assay precision and functional sensitivity (≤6.4 pg/ml) generally met these criteria, but with occasional evidence of greater variability, particularly at lower concentrations. Dilution linearity was acceptable with occasional low recovery. Acceptable recovery of kit calibrators from rat serum confirmed the absence of matrix effects. Matched serum and plasma samples gave comparable results. The signal increased on freezing, remained constant for ≥3 freeze-thaw cycles and was generally stable for at least 8 weeks. Mean inhibin B ranged from 33.5 to 140.6 pg/ml in adult rats across laboratories, with some evidence for a decline from 6 to 9 weeks of age. Power calculations using preliminary reference range data indicated 10 animals/group would generally detect a 40% decrease in inhibin B at AstraZeneca, but laboratories with lower control values would require larger groups.
The assay meets the analytical performance criteria; however, precision at the low end of the standard curve, biological variability, and low control values observed in some laboratories indicate that the utility of the assay may be limited in some laboratories.